Effects of RU486 on Breast Cancer Cells
Author Information
Author(s): Lin V C-L, Aw S E, Ng E H, Ng E H-L, Tan M G-K
Primary Institution: Singapore General Hospital
Hypothesis
How does RU486 affect cell growth and differentiation in PR-transfected MDA-MB-231 breast cancer cells?
Conclusion
RU486 can act as both a progesterone antagonist and agonist, inducing distinct morphological and molecular changes compared to progesterone.
Supporting Evidence
- RU486 inhibited cell growth by arresting cells in the G0/G1 phase of the cell cycle.
- Unlike progesterone, RU486 induced a multipolar, stellate morphology in treated cells.
- RU486 significantly stimulated the activation of p44/p42 MAP kinases, while progesterone inhibited it.
Takeaway
RU486, a drug that blocks progesterone, can also act like progesterone in some ways, but it changes the cells differently than progesterone does.
Methodology
The study used PR-transfected MDA-MB-231 breast cancer cells to compare the effects of RU486 and progesterone on cell growth and molecular activation.
Limitations
The study may not fully represent the effects of RU486 in other cell types or in clinical settings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website